Omeros OMER
NASDAQ OMER
$18.15 +0.85 (+4.91%)
At close: Nov 11, 2026 · 4:00 PM EST

Omeros (OMER) Gains from Sales and Divestitures (2014)

Updated

Omeros' Gains from Sales and Divestitures was $237.59 million in FY2025.

Analysis

Omeros (OMER) Gains from Sales and Divestitures (2014) Analysis & Trends

  • Gains from Sales and Divestitures shows a four-year compound annual growth rate of -6.5% (FY2021 to FY2025).
  • The FY2025 figure marks the highest annual Gains from Sales and Divestitures since FY2021.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $310.56 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Omeros 234.42 Mn -206.99 Mn 27.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 9,000.00
API Access

Omeros Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OMER&period=max&api_key=YOUR_API_KEY